The surgical imaging market has immense growth potential. Surgeons often struggle to confirm adequate blood flow in vessels and tissue during 100 million procedures annually (out of 450 million total).
Thanks to bold, quantum-inspired biosensing from the founder's work at UF's Quantum Theory Project, Viewflow enables surgeons to point and visualize blood flow as augmented reality anytime during open surgery. This eliminates invasive, time-consuming methods like injecting fluorescent dyes for tissue perfusion or attaching ultrasound probes to fragile vessels, approaches that are slow, risky, and outdated.
As a non-contact device, Viewflow is safer, faster, and will save hospitals money. Studies show tools that help assess tissue perfusion during breast reconstruction and heart bypass reduce complications and save hospitals over $700 per case.
Overview of Viewflow
Viewflow harnesses safe, invisible LED and laser lights, powered by proprietary AI-driven HYVE™ algorithms and ultra-fast computing, to provide instant, high-definition blood flow maps. Trained on 300 pig hearts, this quantum-inspired tool surpasses slower ultrasound or dye methods by revealing real-time flow from vessels into tissue without requiring patient contact.
Viewflow's FDA Class I listing positions it as a low-risk device ready for market, de-risking investment and accelerating commercialization.
Market Opportunity
The $30 billion global surgical imaging and flow assessment market is projected to grow at a 10% annual rate, driven by aging populations and increasing demand for improved outcomes. Viewflow is ideally positioned to capture this expansion.
Team Expertise
Jim Sund's Duke MBA & Engineering PhD and published research from UF's Quantum Theory Project drive his expertise in business, science, and engineering. His track record includes licensing a cheminformatics platform to Roche and Merck, as well as consulting for Fortune 500 firms such as Lenovo.
The team includes top engineers, such as Jeff H. (ex-Cisco Principal Software Engineer) and Luke B. (Duke MEM & Biomedical Engineering), guided by clinical advisors from Duke, Houston Methodist, and Rutgers, as well as former FDA/CMS members and European collaborators at the University of Zurich, ensuring a practical and sustainable impact.
Commercialization Plans
Viewflow has mitigated early risks and attained FDA listing and is ready to enter a growing market where surgeons rely on decades-old flow assessment tools.
This $1.2 million raise ($500,000 is still available as of July 2025) will build product credibility by surgeons using ViewFlow in ORs. The results will fuel whitepapers, publications, and presentations.
A follow-on $5M raise will scale pilot studies, new clinical claims, and SaaS sales to target $70M revenue by Year 5:
- $2M (40%): AI enhancements and handheld device R&D
- $1.25M (25%): Clinical trials (starting with 60 patients)
- $750K (15%): New regulatory claims for U.S./Europe
- $1M (20%): Sales/marketing for 20 SaaS deals in Year 1, scaling to 800 by Year 5
Call to Action for Investors
By investing in Viewflow Medical, you join a proven team transforming surgery in a multi-billion-dollar market. This de-risked opportunity offers high-growth potential and significant returns as we scale to $70 million in revenue. Whether you're an individual, a family office, or a venture enthusiast from any background, your support will drive life-saving innovation and reduce global healthcare costs.
Invest online (password: 3) at https://www.viewflow.ai/invest.
For details, email shareholder@viewflowmedical.com.
Join the Conversation